Probably Genetic
Probably Genetic, formerly known as Aiwa Health, is a healthcare company based in San Francisco, specializing in diagnostics and genetic testing for over 4,000 diseases to facilitate early diagnoses and treatment.
Company History
Probably Genetic, formerly known as Aiwa Health, is headquartered in San Francisco, CA, USA. The company operates within the healthcare diagnostics industry, focusing on genetic testing for rare diseases. Probably Genetic is part of the Y Combinator Winter 2019 batch. The company's mission is to help the 200 million rare genetic disease patients find out what they have, with a team of 9 employees dedicated to this cause.
Services
Probably Genetic offers a range of services aimed at diagnosing rare diseases through genetic testing. The services include no-cost testing for rare diseases, enabling patients to determine their eligibility for free at-home genetic testing. The company provides a symptom checker on their website for eligibility assessments and utilizes digital phenotyping to identify undiagnosed rare disease patients online. Tests are performed in a CLIA-certified and CAP-accredited lab, ensuring high standards in genetic analysis. The company offers services across the United States, America/Canada, and remotely.
Products
Probably Genetic provides a Patient Intelligence Platform for Genetic Diseases, aiding drug developers and patient advocacy groups by offering a data platform. This platform supports compliant communication with patients, access to diagnoses, clinical trials, and treatments. The company also offers a service for prevalence modeling to predict the locations of undiagnosed patients and has a diagnostic yield of up to 55% for at-home genetic testing.
Technological Innovations
Probably Genetic leverages machine learning and digital phenotyping in its approach to genetic testing. These technologies enable the analysis of disease states through at-home testing. The data platform used by Probably Genetic supports drug developers and patient advocacy groups in connecting with patients as early as possible. The company's sponsored programs allow partners to offer no-cost testing to eligible patients, further enhancing early diagnosis and treatment opportunities.